Y Intercept Hong Kong Ltd Takes Position in Hologic, Inc. (NASDAQ:HOLX)

Y Intercept Hong Kong Ltd purchased a new stake in Hologic, Inc. (NASDAQ:HOLX) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 24,363 shares of the medical equipment provider’s stock, valued at approximately $1,985,000.

Other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in Hologic by 0.8% during the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock valued at $847,944,000 after purchasing an additional 81,057 shares in the last quarter. FMR LLC boosted its holdings in Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after buying an additional 2,174,093 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in Hologic by 0.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock worth $208,051,000 after buying an additional 18,774 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Hologic by 8.6% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock valued at $200,952,000 after acquiring an additional 195,285 shares during the last quarter. Finally, Black Creek Investment Management Inc. lifted its position in shares of Hologic by 60.9% in the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after acquiring an additional 885,524 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Buying and Selling at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.75% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently commented on the company. Jefferies Financial Group initiated coverage on Hologic in a research report on Tuesday. They set a “hold” rating and a $85.00 price target for the company. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Evercore ISI upped their price objective on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. UBS Group increased their price objective on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. boosted their target price on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, Hologic has a consensus rating of “Moderate Buy” and an average target price of $89.50.

Hologic Stock Up 1.4 %

Shares of NASDAQ:HOLX opened at $76.83 on Wednesday. The company has a market capitalization of $17.44 billion, a price-to-earnings ratio of 23.07, a PEG ratio of 2.37 and a beta of 0.96. Hologic, Inc. has a 12-month low of $68.15 and a 12-month high of $84.67. The business has a 50-day moving average price of $79.62 and a 200 day moving average price of $78.60. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. During the same period last year, the business earned $0.89 earnings per share. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. Sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.